This is very positive, although only for screening before TNF alpha so not a huge market. I was more concerned with the Canadian guidelines which came out at the same time and seem to be recommending the TST ahead of IGRAs in nearly all situations. The problem here is that the CDC may be more inclined to follow the Canadian guidelines when they put out their In Tube guidelines, especially as they were criticised for being too bullish on the use of 2G in the guidelines for that version.